The rationale for using such a combination originates from the fact that VEGF impairs the function of anti-cancer T cells [16–20]; hence VEGF inhibition will enhance T cells function, and checkpoint blockade could therefore significantly advance antitumor therapy. The gene discussed is VEGFA; the disease is cancer.